REFERENCES
1. Zhu D, Brookes DH, Busia A, et al. Optimal trade-off control in machine learning-based library design, with application to adeno-associated virus (AAV) for gene therapy. Sci Adv. 2024;10:eadj3786.
2. Müller OJ, Kaul F, Weitzman MD, et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol. 2003;21:1040-6.
3. Wang JH, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024;9:78.
4. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358-78.
5. Li W, Samulski JR. 743. Directed evolution of adeno-associated virus (AAV) by DNA shuffling yields enhanced gene delivery vectors. Mol Ther. 2006;13:S287.
6. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol. 2006;24:198-204.
7. Fu X, Suo H, Zhang J, Chen D. Machine-learning-guided directed evolution for AAV capsid engineering. Curr Pharm Des. 2024;30:811-24.
8. Guo J, Lin LF, Oraskovich SV, Rivera de Jesús JA, Listgarten J, Schaffer DV. Computationally guided AAV engineering for enhanced gene delivery. Trends Biochem Sci. 2024;49:457-69.
9. Yang C, Ye W, Li Q. Review of the performance optimization of parallel manipulators. Mech Mach Theory. 2022;170:104725.
10. Kawakami T, Murakami H. Genetically encoded libraries of nonstandard peptides. J Nucleic Acids. 2012;2012:713510.
11. Zempel H. Genetic and sporadic forms of tauopathies-TAU as a disease driver for the majority of patients but the minority of tauopathies. Cytoskeleton. 2024;81:66-70.
12. Langerscheidt F, Wied T, Al Kabbani MA, van Eimeren T, Wunderlich G, Zempel H. Genetic forms of tauopathies: inherited causes and implications of Alzheimer’s disease-like TAU pathology in primary and secondary tauopathies. J Neurol. 2024;271:2992-3018.
13. Walkey CJ, Snow KJ, Bulcha J, et al. A comprehensive atlas of AAV tropism in the mouse. Mol Ther. 2025;33:1282-99.
14. Keng CT, Guo K, Liu YC, et al. Multiplex viral tropism assay in complex cell populations with single-cell resolution. Gene Ther. 2022;29:555-65.
15. Ravindra Kumar S, Miles TF, Chen X, et al. Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types. Nat Methods. 2020;17:541-50.
16. Hoose A, Vellacott R, Storch M, Freemont PS, Ryadnov MG. DNA synthesis technologies to close the gene writing gap. Nat Rev Chem. 2023;7:144-61.
17. Zhao Q, Peng H, Ma Y, Yuan H, Jiang H. In vivo applications and toxicities of AAV-based gene therapies in rare diseases. Orphanet J Rare Dis. 2025;20:368.
18. Piccolo P, Brunetti-Pierri N. Current and emerging issues in adeno-associated virus vector-mediated liver-directed gene therapy. Hum Gene Ther. 2025;36:77-87.
19. Zwi-Dantsis L, Mohamed S, Massaro G, Moeendarbary E. Adeno-associated virus vectors: principles, practices, and prospects in gene therapy. Viruses. 2025;17:239.
